Cargando…

Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study

BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Finci, Iris, Albertini, Audrey, Merker, Matthias, Andres, Sönke, Bablishvili, Nino, Barilar, Ivan, Cáceres, Tatiana, Crudu, Valeriu, Gotuzzo, Eduardo, Hapeela, Nchimunya, Hoffmann, Harald, Hoogland, Christine, Kohl, Thomas A, Kranzer, Katharina, Mantsoki, Anna, Maurer, Florian P, Nicol, Mark P, Noroc, Ecaterina, Plesnik, Sara, Rodwell, Timothy, Ruhwald, Morten, Savidge, Theresa, Salfinger, Max, Streicher, Elizabeth, Tukvadze, Nestani, Warren, Robin, Zemanay, Widaad, Zurek, Anna, Niemann, Stefan, Denkinger, Claudia M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436784/
https://www.ncbi.nlm.nih.gov/pubmed/35907429
http://dx.doi.org/10.1016/S2666-5247(22)00116-1
_version_ 1784781449330688000
author Finci, Iris
Albertini, Audrey
Merker, Matthias
Andres, Sönke
Bablishvili, Nino
Barilar, Ivan
Cáceres, Tatiana
Crudu, Valeriu
Gotuzzo, Eduardo
Hapeela, Nchimunya
Hoffmann, Harald
Hoogland, Christine
Kohl, Thomas A
Kranzer, Katharina
Mantsoki, Anna
Maurer, Florian P
Nicol, Mark P
Noroc, Ecaterina
Plesnik, Sara
Rodwell, Timothy
Ruhwald, Morten
Savidge, Theresa
Salfinger, Max
Streicher, Elizabeth
Tukvadze, Nestani
Warren, Robin
Zemanay, Widaad
Zurek, Anna
Niemann, Stefan
Denkinger, Claudia M
author_facet Finci, Iris
Albertini, Audrey
Merker, Matthias
Andres, Sönke
Bablishvili, Nino
Barilar, Ivan
Cáceres, Tatiana
Crudu, Valeriu
Gotuzzo, Eduardo
Hapeela, Nchimunya
Hoffmann, Harald
Hoogland, Christine
Kohl, Thomas A
Kranzer, Katharina
Mantsoki, Anna
Maurer, Florian P
Nicol, Mark P
Noroc, Ecaterina
Plesnik, Sara
Rodwell, Timothy
Ruhwald, Morten
Savidge, Theresa
Salfinger, Max
Streicher, Elizabeth
Tukvadze, Nestani
Warren, Robin
Zemanay, Widaad
Zurek, Anna
Niemann, Stefan
Denkinger, Claudia M
author_sort Finci, Iris
collection PubMed
description BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. METHODS: In a prospective multicentre observational study, 900 clinical M tuberculosis complex isolates were collected from adults with drug-resistant tuberculosis in five high-endemic tuberculosis settings around the world (Georgia, Moldova, Peru, South Africa, and Viet Nam) between Dec 5, 2014, and Dec 12, 2017. Minimum inhibitory concentrations (MICs) and resulting binary phenotypic AST results for up to nine antituberculosis drugs were determined and correlated with resistance-conferring mutations identified by WGS. FINDINGS: Considering WHO-endorsed critical concentrations as reference, WGS had high accuracy for prediction of resistance to isoniazid (sensitivity 98·8% [95% CI 98·5–99·0]; specificity 96·6% [95% CI 95·2–97·9]), levofloxacin (sensitivity 94·8% [93·3–97·6]; specificity 97·1% [96·7–97·6]), kanamycin (sensitivity 96·1% [95·4–96·8]; specificity 95·0% [94·4–95·7]), amikacin (sensitivity 97·2% [96·4–98·1]; specificity 98·6% [98·3–98·9]), and capreomycin (sensitivity 93·1% [90·0–96·3]; specificity 98·3% [98·0–98·7]). For rifampicin, pyrazinamide, and ethambutol, the specificity of resistance prediction was suboptimal (64·0% [61·0–67·1], 83·8% [81·0–86·5], and 40·1% [37·4–42·9], respectively). Specificity for rifampicin increased to 83·9% when borderline mutations with MICs overlapping with the critical concentration were excluded. Consequently, we highlighted mutations in M tuberculosis complex isolates that are often falsely identified as susceptible by phenotypic AST, and we identified potential novel resistance-conferring mutations. INTERPRETATION: The combined analysis of mutations and quantitative phenotypes shows the potential of WGS to produce a refined interpretation of resistance, which is needed for individualised therapy, and eventually could allow differential drug dosing. However, variability of MIC data for some M tuberculosis complex isolates carrying identical mutations also reveals limitations of our understanding of the genotype and phenotype relationships (eg, including epistasis and strain genetic background). FUNDING: Bill & Melinda Gates Foundation, German Centre for Infection Research, German Research Foundation, Excellence Cluster Precision Medicine of Inflammation (EXC 2167), and Leibniz ScienceCampus EvoLUNG.
format Online
Article
Text
id pubmed-9436784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd
record_format MEDLINE/PubMed
spelling pubmed-94367842022-09-09 Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study Finci, Iris Albertini, Audrey Merker, Matthias Andres, Sönke Bablishvili, Nino Barilar, Ivan Cáceres, Tatiana Crudu, Valeriu Gotuzzo, Eduardo Hapeela, Nchimunya Hoffmann, Harald Hoogland, Christine Kohl, Thomas A Kranzer, Katharina Mantsoki, Anna Maurer, Florian P Nicol, Mark P Noroc, Ecaterina Plesnik, Sara Rodwell, Timothy Ruhwald, Morten Savidge, Theresa Salfinger, Max Streicher, Elizabeth Tukvadze, Nestani Warren, Robin Zemanay, Widaad Zurek, Anna Niemann, Stefan Denkinger, Claudia M Lancet Microbe Articles BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. METHODS: In a prospective multicentre observational study, 900 clinical M tuberculosis complex isolates were collected from adults with drug-resistant tuberculosis in five high-endemic tuberculosis settings around the world (Georgia, Moldova, Peru, South Africa, and Viet Nam) between Dec 5, 2014, and Dec 12, 2017. Minimum inhibitory concentrations (MICs) and resulting binary phenotypic AST results for up to nine antituberculosis drugs were determined and correlated with resistance-conferring mutations identified by WGS. FINDINGS: Considering WHO-endorsed critical concentrations as reference, WGS had high accuracy for prediction of resistance to isoniazid (sensitivity 98·8% [95% CI 98·5–99·0]; specificity 96·6% [95% CI 95·2–97·9]), levofloxacin (sensitivity 94·8% [93·3–97·6]; specificity 97·1% [96·7–97·6]), kanamycin (sensitivity 96·1% [95·4–96·8]; specificity 95·0% [94·4–95·7]), amikacin (sensitivity 97·2% [96·4–98·1]; specificity 98·6% [98·3–98·9]), and capreomycin (sensitivity 93·1% [90·0–96·3]; specificity 98·3% [98·0–98·7]). For rifampicin, pyrazinamide, and ethambutol, the specificity of resistance prediction was suboptimal (64·0% [61·0–67·1], 83·8% [81·0–86·5], and 40·1% [37·4–42·9], respectively). Specificity for rifampicin increased to 83·9% when borderline mutations with MICs overlapping with the critical concentration were excluded. Consequently, we highlighted mutations in M tuberculosis complex isolates that are often falsely identified as susceptible by phenotypic AST, and we identified potential novel resistance-conferring mutations. INTERPRETATION: The combined analysis of mutations and quantitative phenotypes shows the potential of WGS to produce a refined interpretation of resistance, which is needed for individualised therapy, and eventually could allow differential drug dosing. However, variability of MIC data for some M tuberculosis complex isolates carrying identical mutations also reveals limitations of our understanding of the genotype and phenotype relationships (eg, including epistasis and strain genetic background). FUNDING: Bill & Melinda Gates Foundation, German Centre for Infection Research, German Research Foundation, Excellence Cluster Precision Medicine of Inflammation (EXC 2167), and Leibniz ScienceCampus EvoLUNG. Elsevier Ltd 2022-09 /pmc/articles/PMC9436784/ /pubmed/35907429 http://dx.doi.org/10.1016/S2666-5247(22)00116-1 Text en © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Finci, Iris
Albertini, Audrey
Merker, Matthias
Andres, Sönke
Bablishvili, Nino
Barilar, Ivan
Cáceres, Tatiana
Crudu, Valeriu
Gotuzzo, Eduardo
Hapeela, Nchimunya
Hoffmann, Harald
Hoogland, Christine
Kohl, Thomas A
Kranzer, Katharina
Mantsoki, Anna
Maurer, Florian P
Nicol, Mark P
Noroc, Ecaterina
Plesnik, Sara
Rodwell, Timothy
Ruhwald, Morten
Savidge, Theresa
Salfinger, Max
Streicher, Elizabeth
Tukvadze, Nestani
Warren, Robin
Zemanay, Widaad
Zurek, Anna
Niemann, Stefan
Denkinger, Claudia M
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
title Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
title_full Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
title_fullStr Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
title_full_unstemmed Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
title_short Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
title_sort investigating resistance in clinical mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436784/
https://www.ncbi.nlm.nih.gov/pubmed/35907429
http://dx.doi.org/10.1016/S2666-5247(22)00116-1
work_keys_str_mv AT finciiris investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT albertiniaudrey investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT merkermatthias investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT andressonke investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT bablishvilinino investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT barilarivan investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT cacerestatiana investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT cruduvaleriu investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT gotuzzoeduardo investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT hapeelanchimunya investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT hoffmannharald investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT hooglandchristine investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT kohlthomasa investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT kranzerkatharina investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT mantsokianna investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT maurerflorianp investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT nicolmarkp investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT norocecaterina investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT plesniksara investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT rodwelltimothy investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT ruhwaldmorten investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT savidgetheresa investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT salfingermax investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT streicherelizabeth investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT tukvadzenestani investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT warrenrobin investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT zemanaywidaad investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT zurekanna investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT niemannstefan investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy
AT denkingerclaudiam investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy